Specific targeting of HER2-positive human breast carcinoma SK-BR-3 cells by amygdaline-ZHER2 affibody conjugate.
In conclusion, the amygdalin-ZHER2 affibody conjugate may be considered as a valuable candidate for specific treatment of breast cancer patients with overexpression of HER2. However, further in vivo studies are required to explain the antitumoral effects of constructed amygdalin-ZHER2 affibody conjugate.
PMID: 32929653 [PubMed - as supplied by publisher]
Source: Molecular Biology Reports - Category: Molecular Biology Authors: Moradipoodeh B, Jamalan M, Zeinali M, Fereidoonnezhad M, Mohammadzadeh G Tags: Mol Biol Rep Source Type: research
More News: Biology | Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Gastroenteritis | Genetics | HER2 | Molecular Biology | Study